ADC Therapeutics SA

Welcome to the ADC Therapeutics Third Quarter 2021 Financial Results Conference Call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star then 1 on your touch-tone phone. I will now turn the call over to Amanda Hamilton, Investor Relations Manager. Amanda, you may begin.

Thank you, operator. This morning we issued a press release announcing our third quarter 2021 financial results and business update. This release is available on the ADCT website at ir.adctherapeutics.com under the press releases section. On today's call, Chris Martin, Chief Executive Officer, Jennifer Herron, Chief Commercial Officer, Joe Camardo, Chief Medical Officer, and Jen Creel, Chief Financial Officer, we'll discuss recent business highlights and review our third quarter 2021 financial results before opening the call for questions. As a reminder, this conference call may contain forward-looking statements. Such statements are subject to risks and uncertainties. For additional information concerning forward-looking statements and factors that could cause actual results to differ materially from those expressed or implied in these statements, we refer you to the section titled Cautionary Statement Regarding Forward-Looking Statements in Exhibit 99.3 of our report on Form 6-K filed with the U.S. Securities and Exchange Commission earlier today. Such statements speak only as of the date of this conference call, and we expressly disclaim any application or undertaking to update these forward-looking statements unless required to do so by applicable law. Today's presentation also includes non-IFRS financial measures. These non-IFRS measures have limitations as financial measures and should be considered in addition to and not in isolation or as a substitute for the information prepared in accordance with IFRS. You should refer to the information contained in the company's third quarter earnings release for definitional information and reconciliations of historical non-IFRS measures to the comparable IFRS financial measures. It is now my pleasure to pass the call over to our CEO, Chris Martin. Chris?

Thanks, Amanda, and thank you, everyone, for joining us today. I'm very pleased to share an update of our progress during the third quarter. We successfully executed on our key objectives, driving the Zynlonta launch, advancing the R&D pipeline, and achieving several important corporate development goals. We are now approximately six months into the Zynlonta launch, and we are encouraged by what we have accomplished to date, delivering $13.1 million in net sales in our first quarter of the launch. We have generated good momentum behind the launch, driven by the unique product profile, the significant unmet need in third-line plus DLBCL, and the strong execution of our highly experienced team of sales and medical professionals. Jennifer Herron, our Chief Commercial Officer, will share more details on our launch a little later in this call. Buoyed by our first FDA approval, we remain committed to expanding our geographic footprint to provide Zynlanta to as many patients as possible worldwide with relapsed or refractory DLBCL. The EMA validated our marketing authorization application and we received orphan drug designation in Europe. The Overland ADCT joint venture also made tremendous progress with the initiation of the pivotal phase two bridging study in China which is intended to serve as a basis for a regulatory filing in China. In addition to geographic expansion, we are also continuing to evaluate Synlonza in combination with other agents in earlier line opportunities in DLBCL and as a single agent in follicular lymphoma. On the R&D front, we continue to advance our pipeline programs, which are important for driving long-term value for the company. We initiated the Phase 1 study for ADCT901 targeting CAC1 and entered into a collaboration with the NCI for the development of ADCT701 targeting DLK1. For CAMI, we continue to advance the Phase 2 trial in relapsed refractory Hodgkin lymphoma and the Phase 1B study in solid tumors. Joe Camardo, our chief medical officer, will elaborate on our key programs in a few moments. Finally, during the quarter, we extended our cash runway by entering into a financing agreement with healthcare royalty partners for up to $325 million for the continued development of the commercialization of Zynlonta and Cami. I would now like to turn the call over to Jennifer to provide some insights on our progress with the Zynlonta launch. Jennifer.